Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > New Corporate Presentation up

<< Previous

Bullboard Posts

Next >>

Comment by houbahopon Mar 16, 2022 11:17am

69 Views

Post# 34518436

RE:RE:New Corporate Presentation up

I am quite surprised you haven't been put on "ignore" for posting these comments.
I have warned this board for years (maybe a decade?) about Theratechnologies:

- Spending hundreds of millions of $$$ on research that would not create value for shareholders even with results good enough to bring to commercialization.

- Total lack of transparency.

- Look at the Retained Earnings row on the Balance Sheet. Latest figure: -$336m

<< Previous

Bullboard Posts

Next >>

Increasing summer travel could see these airline stocks soar